Zentalis Pharmaceuticals (ZNTL) Other financing activities (2020 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Other financing activities of $331000.0 for Q1 2026, up 75.13% year-over-year from $189000.0 in Q1 2025, and up 187.83% quarter-over-quarter from $115000.0 in Q3 2025.
Zentalis Pharmaceuticals (ZNTL) Other financing activities (2020 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Other financing activities history runs 7 years deep, the most recent figure standing at $331000.0 for Q1 2026.
- In Q1 2026, Other financing activities rose 75.13% year-over-year to $331000.0; the TTM figure through Mar 2026 stood at $446000.0 (up 53.79% YoY), while the FY2025 annual figure was $304000.0, down 12.89% from the prior year.
- Other financing activities for Q1 2026 stood at $331000.0, up from $115000.0 in the prior quarter.
- The five-year high for Other financing activities was $1.3 million in Q1 2022, with the low at $9000.0 in Q2 2024.
- The 5-year median for Other financing activities is $309000.0 (2023), against an average of $440615.4.
- The sharpest annual moves came in 2023 and 2024: Other financing activities surged 495.57% in 2023, then plunged 99.04% in 2024.
- Zentalis Pharmaceuticals' Other financing activities stood at $1.1 million in 2022, then sank by 72.31% to $309000.0 in 2023, then tumbled by 70.23% to $92000.0 in 2024, then climbed by 25.0% to $115000.0 in 2025, then jumped by 187.83% to $331000.0 in 2026.
- Business Quant data shows ZNTL's Other financing activities at $331000.0 in Q1 2026, $115000.0 in Q3 2025, and $189000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65,000.00 |
| Jun 30, 2026 | 65,000.00 |
| Mar 31, 2026 | 331,000.00 |
| Mar 31, 2026 | 331,000.00 |
| Sep 30, 2025 | 115,000.00 |
| Sep 30, 2025 | 115,000.00 |
| Mar 31, 2025 | 189,000.00 |
| Mar 31, 2025 | 189,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Sep 30, 2023 | 309,000.00 |
| Sep 30, 2023 | 309,000.00 |
| Jun 30, 2023 | 941,000.00 |
| Jun 30, 2023 | 941,000.00 |
| Mar 31, 2023 | 373,000.00 |
| Mar 31, 2023 | 373,000.00 |